Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
Novocure Reports Third Quarter 2024 Financial Results
07:00am, Wednesday, 30'th Oct 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Third Quarter 2024 Financial Results.
NovoCure: There Is Still More Upside
11:00am, Wednesday, 16'th Oct 2024
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment which resulted in positive price action. The lung cancer market will significanly increase Novocure's scale, on top
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
07:28am, Wednesday, 16'th Oct 2024
On Tuesday, the FDA approved NovoCure's NVCR Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progr
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
04:45am, Wednesday, 16'th Oct 2024
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
04:43pm, Tuesday, 15'th Oct 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhi
Novocure to Report Third Quarter 2024 Financial Results
07:00am, Tuesday, 01'st Oct 2024
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open.
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Present Real-World Data at ESMO 2024.
Why NovoCure Stock Dived by 13% This Week
05:19pm, Friday, 06'th Sep 2024
The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025.
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet
11:01am, Friday, 16'th Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positiv
Biotech stocks: Which drugmakers are worth a buy?
05:13pm, Monday, 12'th Aug 2024
While the pharma space has seen growing excitement over weight-loss drugs from Eli Lilly (LLY) and Novo Nordisk's (NVO) latest earnings, investors are increasingly curious over the types of innovation
New Strong Buy Stocks for August 1st
08:21am, Thursday, 01'st Aug 2024
NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade
10:56am, Tuesday, 30'th Jul 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the posit
NovoCure Limited: A Post Q2 Analysis
12:34pm, Friday, 26'th Jul 2024
Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers. The company has beat expectations for both its first and second quarte
NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript
12:35pm, Thursday, 25'th Jul 2024
NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
09:10am, Thursday, 25'th Jul 2024
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.
